
CLAIMS

1. A compound of formula (I):



(I)

wherein:

- R^1 represents a group selected from:

a) phenyl ring unsubstituted or substituted by 1 or 2 groups selected from halogen atom, linear or branched C_1-C_3 haloalkyl, linear or branched C_1-C_3 alkyl, linear or branched C_1-C_3 alkoxy, cyano group and hydroxy group,

b) 5- or 6-membered heteroaryl ring unsubstituted or substituted by 1 or 2 groups selected from halogen atom, linear or branched C_1-C_3 haloalkyl, linear or branched C_1-C_3 alkyl, linear or branched C_1-C_3 alkoxy, cyano group and hydroxy group,

- R^2 is a group selected from:

a) hydrogen atom,

b) linear or branched C_1-C_3 alkyl optionally substituted by 1, 2 or 3 halogen atoms,

- R^3 represents a group selected from:

a) hydrogen atom,

b) linear or branched C_1-C_3 alkyl optionally substituted by 1, 2 or 3 halogen atoms,

c) halogen atom,

- R^4 and R^5 represent independently a group selected from:

a) hydrogen atom,

b) linear or branched C_1-C_3 alkyl optionally substituted by 1, 2 or 3 halogen atoms,

c) halogen atom,

- n is an integer from 0 to 3,

- R^6 represents a group selected from the group consisting of:

a) $-N(R^7)(R^8)$, wherein R^7 and R^8 represent independently a linear or branched C_1-C_6 alkyl group or a hydrogen atom, and

b) saturated 4- to 10-membered, monocyclic or bicyclic, nitrogen-containing heterocyclyl optionally comprising another heteroatom selected from the group consisting of oxygen and nitrogen, said heterocyclyl being optionally substituted by a group selected from C_1-C_3 alkyl group,

or a pharmaceutically acceptable salt thereof.

2. The compound or a pharmaceutically acceptable salt thereof according to claim 1 wherein R^2, R^4 and R^5 represent hydrogen atom.

3. The compound or a pharmaceutically acceptable salt thereof according to claim 1 or claim 2 wherein R^3 represents methyl group.

4. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 3 wherein R^1 represents a phenyl ring substituted by 1 or 2 halogen atoms.

5. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4 wherein n is an integer from 1 to 2 and R^6 represents a $-N(R^7)(R^8)$ group.

6. The compound or a pharmaceutically acceptable salt thereof according to claim 5 wherein R^7 and R^8 represent independently a group selected from linear C_1-C_3 alkyl group and hydrogen atom.

7. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4 wherein R^6 represents a saturated 6-membered heterocyclic group containing 1 or 2 nitrogen atoms, optionally substituted by a methyl group.

8. The compound or a pharmaceutically acceptable salt thereof according to claim 7 wherein R^6 represents a group selected from a piperazinyl and a piperidinyl group.

9. The compound or a pharmaceutically acceptable salt thereof according to claim 1 wherein R^2, R^4 and R^5 represent hydrogen atom, R^3 represents linear C_1-C_3 alkyl, R^1 represents a phenyl ring substituted by 1 or 2 halogen atoms, n is an integer from 0 to 2 and R^6 represents a group selected from the group consisting of:

a) -N(R^7)(R^8), wherein R^7 and R^8 are selected from linear C_1-C_3 alkyl group and hydrogen atom,

b) a saturated 6-membered heterocyclic group containing 1 or 2 nitrogen atoms, optionally substituted by a methyl group, and

c) 1-aza-bicyclo[2.2.2]octanyl.

10. The compound or a pharmaceutically acceptable salt thereof according to claim 1 which is selected from the group consisting of:

2-(dimethylamino)ethyl 3-fluoro-5-(2-(3-(6-methylpyridin-2-yl)-4-(quinolin-4-yl)-1*H*-pyrazol-1-yl)acetamido)benzoate;

2-(dimethylamino)ethyl 5-(2-(3-(6-methylpyridin-2-yl)-4-(quinolin-4-yl)-1*H*-pyrazol-1-yl)acetamido)nicotinate;

2-(dimethylamino)ethyl 6-(2-(3-(6-methylpyridin-2-yl)-4-(quinolin-4-yl)-1*H*-pyrazol-1-yl)acetamido)nicotinate;

2-morpholinoethyl 3-fluoro-5-(2-(3-(6-methylpyridin-2-yl)-4-(quinolin-4-yl)-1*H*-pyrazol-1-yl)acetamido)benzoate;

2-(dimethylamino)ethyl 5-(2-(3-(6-methylpyridin-2-yl)-4-(quinolin-4-yl)-1*H*-pyrazol-1-yl)acetamido)picolinate;

2-(4-methylpiperazin-1-yl)ethyl 3-fluoro-5-(2-(3-(6-methylpyridin-2-yl)-4-(quinolin-4-yl)-1*H*-pyrazol-1-yl)acetamido)benzoate;

2-(diethylamino)ethyl 3-fluoro-5-(2-(3-(6-methylpyridin-2-yl)-4-(quinolin-4-yl)-1*H*-pyrazol-1-yl)acetamido)benzoate;

1-methylpiperidin-4-yl 3-fluoro-5-(2-(3-(6-methylpyridin-2-yl)-4-(quinolin-4-yl)-1*H*-pyrazol-1-yl)acetamido)benzoate;

(1-methylpiperidin-4-yl)methyl 3-fluoro-5-(2-(3-(6-methylpyridin-2-yl)-4-(quinolin-4-yl)-1*H*-pyrazol-1-yl)acetamido)benzoate;

(*R*)-quinuclidin-3-yl 3-fluoro-5-(2-(3-(6-methylpyridin-2-yl)-4-(quinolin-4-yl)-1*H*-pyrazol-1-yl)acetamido)benzoate;

(*S*)-quinuclidin-3-yl 3-fluoro-5-(2-(3-(6-methylpyridin-2-yl)-4-(quinolin-4-yl)-1*H*-pyrazol-1-yl)acetamido)benzoate;

quinuclidin-4-yl 3-fluoro-5-(2-(3-(6-methylpyridin-2-yl)-4-(quinolin-4-yl)-1*H*-pyrazol-1-yl)acetamido)benzoate;

2-(azetidin-1-yl)ethyl 3-fluoro-5-(2-(3-(6-methylpyridin-2-yl)-4-(quinolin-4-yl)-1*H*-pyrazol-1-yl)acetamido)benzoate;

2-(aziridin-1-yl)ethyl 3-fluoro-5-(2-(3-(6-methylpyridin-2-yl)-4-(quinolin-4-yl)-1*H*-pyrazol-1-yl)acetamido)benzoate;

2-(methylamino)ethyl 3-fluoro-5-(2-(3-(6-methylpyridin-2-yl)-4-(quinolin-4-yl)-1*H*-pyrazol-1-yl)acetamido)benzoate;

2-aminoethyl 3-fluoro-5-(2-(3-(6-methylpyridin-2-yl)-4-(quinolin-4-yl)-1*H*-pyrazol-1-yl)acetamido)benzoate;

2-(ethylamino)ethyl 3-fluoro-5-(2-(3-(6-methylpyridin-2-yl)-4-(quinolin-4-yl)-1*H*-pyrazol-1-yl)acetamido)benzoate;

2-(isopropylamino)ethyl 3-fluoro-5-(2-(3-(6-methylpyridin-2-yl)-4-(quinolin-4-yl)-1*H*-pyrazol-1-yl)acetamido)benzoate;

2-(piperazin-1-yl)ethyl 3-fluoro-5-(2-(3-(6-methylpyridin-2-yl)-4-(quinolin-4-yl)-1*H*-pyrazol-1-yl)acetamido)benzoate;

piperidin-4-ylmethyl 3-fluoro-5-(2-(3-(6-methylpyridin-2-yl)-4-(quinolin-4-yl)-1*H*-pyrazol-1-yl)acetamido)benzoate; and

piperidin-4-yl 3-fluoro-5-(2-(3-(6-methylpyridin-2-yl)-4-(quinolin-4-yl)-1*H*-pyrazol-1-yl)acetamido)benzoate;

or a pharmaceutically acceptable salt of any one thereof.

11. Use of the compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 10 in the manufacture of a medicament for the treatment of a disease or pathological condition selected from the group consisting of respiratory diseases, fibrotic skin diseases and fibrotic eye diseases.

12. The use according to claim 11 wherein the respiratory disease is selected from the group consisting of: pulmonary fibrosis, asthma, chronic obstructive pulmonary disease, adult respiratory distress syndrome, idiopathic pulmonary fibrosis, interstitial pulmonary fibrosis, pulmonary arterial hypertension and lung cancer.

13. The use according to claim 11 wherein the fibrotic skin disease is selected from the group consisting of: scleroderma, nephrogenic fibrosing dermopathy, mixed connective tissue disease, scleromyxedema, and eosinophilic fasciitis.

14. The use according to claim 11 wherein the fibrotic eye disease is selected from the group consisting of: dry eyes, age-related macular degeneration, scarring in the cornea and conjunctiva, post-cataract fibrosis, proliferative vitreoretinopathy and proliferative diabetic retinopathy.

15. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 10 for use as a medicament.

16. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 10 for use in the treatment of a disease or pathological condition

selected from the group consisting of respiratory diseases, fibrotic skin diseases and fibrotic eye diseases.

17. The compound or a pharmaceutically acceptable salt thereof for use according to claim 16 wherein the respiratory disease is selected from the group consisting of: pulmonary fibrosis, asthma, chronic obstructive pulmonary disease, adult respiratory distress syndrome, idiopathic pulmonary fibrosis, interstitial pulmonary fibrosis, pulmonary arterial hypertension and lung cancer.

18. The compound or a pharmaceutically acceptable salt thereof for use according to claim 16 wherein the fibrotic skin disease is selected from the group consisting of: scleroderma, nephrogenic fibrosing dermopathy, mixed connective tissue disease, scleromyxedema, and eosinophilic fasciitis.


19. The compound or a pharmaceutically acceptable salt thereof for use according to claim 16 wherein the fibrotic eye disease is selected from the group consisting of: dry eyes, age-related macular degeneration, scarring in the cornea and conjunctiva, post-cataract fibrosis, proliferative vitreoretinopathy and proliferative diabetic retinopathy.

20. A pharmaceutical composition comprising the compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 10 and a pharmaceutically acceptable diluent or carrier.

21. The pharmaceutical composition according to claim 20 further comprising a therapeutically effective amount of a therapeutic agent useful for the treatment of a disease or pathological condition selected from the group consisting of respiratory diseases, fibrotic skin diseases and fibrotic eye diseases.

22. A combination product comprising the compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 10 and at least a therapeutic agent useful for the treatment of a disease or pathological condition selected from the group consisting of respiratory diseases, fibrotic skin diseases and fibrotic eye diseases.

23. A compound of formula (II):



(II)

or a salt thereof;

wherein R^1, R^2, R^3, R^4 and R^5 are as defined in any one of claims 1 to 10.

24. The compound or a salt thereof according to claim 23 which is selected from the group consisting of:


3-(2-(3-(6-methylpyridin-2-yl)-4-(quinolin-4-yl)-1H-pyrazol-1-yl)acetamido)-5-fluorobenzoic acid;

5-(2-(3-(6-methylpyridin-2-yl)-4-(quinolin-4-yl)-1H-pyrazol-1-yl)acetamido)picolinic acid; and

6-(2-(3-(6-methylpyridin-2-yl)-4-(quinolin-4-yl)-1H-pyrazol-1-yl)acetamido)pyridine-3-carboxylic acid;

or a salt of any one thereof.

25. A process for the preparation of the compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 10, which comprises reacting a compound of formula (II):



(II)

or a salt thereof;

with a compound of formula (III):



(III)

or a salt thereof;

wherein n, R^1, R^2, R^3, R^4, R^5 and R^6 are as defined in any one of claims 1 to 10.